2015年10月13日星期二

How does DNA operate to drive cell activities?

A research group from Baylor College of Medicine revealed in unparalleled detail the three-dimensional structure of biologically active DNA. Their report is published in the journal Nature Communications online.
"The beautiful double-helical structure we all know and love is not the actual active form of DNA," said Dr. Lynn Zechiedrich, professor in the department of molecular virology and microbiology, and co-contributing author with Dr. Wah Chiu, professor in the Verna and Marrs McLean Department of Biochemistry and Molecular Biology.
Chiu and Zechiedrich, cooperating with Dr. Steven Ludtke and Dr. Michael Schmid, who is also at Baylor College of Medicine, and Dr. Sarah A. Harris of the University of Leeds in the United Kingdom, examined tiny DNA minicircles containing only 336 base pairs, using methods from chemistry, physics, math and computer modeling. Base pairs are the building blocks of genetic material.
Previous studies were on short fragments of linear DNA, but human DNA is constantly moving around in our body, and it coils and uncoils. Researchers can't coil linear DNA and study it, so they had to make circles so the ends would trap the different degrees of winding, according to Zechiedrich.
In the human body, each cell holds about a meter of DNA which is ten million times longer than the tiny circles the team made. In the research, the researchers wound or unwound a single turn when the DNA double helix comprising their circles and used very powerful microscopes to see how the winding changed what the circles looked like.
They did a test to ensure the tiny twisted up DNA circles that they made in the lab were biologically active. They used purified human topoisomerase II alpha. It's an essential enzyme that manipulates DNA and important target of anticancer drugs. The results indicate that the circles must look and act like the much longer DNA that topoisomerases encounter in human cells.
"Being able to observe individual DNA circles allows us to understand the different structures of biologically active DNA. Each of these different structures facilitates how DNA interacts with proteins, other DNA and RNA, and anticancer drugs, adapting to the cell processes required," said Dr. Jonathan Fogg, the other lead author of the publication, also of Baylor College of Medicine.
The researchers hoped to see the opening of base pairs when the DNA was underwound, but they were surprised to see the opening for the overwound DNA. They supposed this disruption of base pairs may cause flexible hinges, allowing the DNA to sharply bend, and it may help to explain how a meter of DNA can be pushed into a single human cell.
What the researchers will be aimed at is to add other components of the cell or anticancer drugs to figure out how the DNA shapes change. More researchers are joining in to get new findings.
Read more:http://www.cusabio.com/catalog-9-1.html

2015年10月11日星期日

New technology developed to sequence genes: faster, better and cheaper

If DNA is called the blueprint of life, RNA is the construction contractor who interprets it. Therefore, it is quite important to sequence RNA for it shows you what is happening inside a cell.
Recently, researchers from UConn Institute of Systems Genomics have sequenced the RNA of the most complicated gene known in nature. What they use is a hand-held sequencer which is not as big as a cell phone.
Genomicists Brenton Graveley from the UConn Institute of Systems Genomics, postdoctoral fellow Mohan Bolisetty, and graduate student Gopinath Rajadinakaran together with UK-based Oxford Nanopore Technologies to show that the company's MinION nanopore sequencer can sequence genes faster, better, and at a much lower cost than the standard technology. Their findings were published in Genome Biology on Sept. 30.
If your genome was a library and every gene was a book, some genes would be straightforward reads, but some would be more like a "Choose Your Own Adventure" novel. Researchers tend to know which version of the gene is actually expressed in the body, but for complicated choose-your-own-adventure genes, it has been impossible. The researchers solved the problem in two parts.
The first was to find a better gene-sequencing technology. They used the old existing technology to sequence genes. This technique won't work for choose-your-own-adventure genes, because if you copy them the way the body does, using RNA, each copy can be slightly or very different from the next. Such different versions of the same gene are called isoforms. When the different isoforms get chopped up and sequenced, it becomes impossible to accurately compare the pieces and figure out which versions of the gene you started with.
Last year, the impossible things became possible. Oxford Nanopore, a company based in the UK, released its new nanopore sequencer, and offered one to Graveley's lab. The nanopore sequencer, called a MinION, works by feeding a single strand of DNA through a tiny pore. The pore can only hold five DNA bases - the 'letters' that spell out our genes - at a time. There are four DNA bases, G, A, T, and C, and 1,024 possible five-base combinations. Each combination creates a different electrical current in the nanopore. GGGGA makes a different current than AGGGG, which is different again than CGGGG. By feeding the DNA through the pore and recording the resulting signal, researchers can read the sequence of the DNA.
In the second part, the researchers chose the most complex one known, Down Syndrome cell adhesion molecule 1 (Dscam1), which controls the wiring of the brain in fruit flies. Dscam1 has the potential of making 38,016 possible isoforms, and every fruit fly has the potential to make every one of them, yet how many of these versions are actually made remains unknown.
Dscam1 looks like this: X-12-X-48-X-33-X-2-X, where X's denote sections that are always the same, and the numbers indicate sections that can vary (the number itself shows how many different options there are for that section).
The researchers had to convert Dscam1 RNA into DNA to study how many different isoforms of Dscam1 actually exist in a fly's brain. If DNA is the book or set of instructions, RNA is the transcriber that copies the book so that it can be translated into a protein. The DNA includes the instructions for all 38,016 isoforms of the Dscam1 gene, while each individual Dscam1 RNA contains the instructions for just one. No one had yet used a MinION to sequence copies of RNA, and though it was likely it could be done, demonstrating it and showing how well it worked would be a substantial advance in the field.
Rajadinakaran took a fruit fly brain, extracted the RNA and converted it into DNA, isolated the DNA copies of the Dscam1 RNAs, and then ran them through the MinION's nanopores. In this one experiment, they not only found 7,899 of the 38,016 possible isoforms of Dscam1 were expressed but also that many more, if not all versions are likely to be expressed.
The study shows that gene sequencing technology can now be accessed by more researchers than before, since the MinION is both relatively inexpensive and highly portable.
"This type of cutting-edge work puts UConn at the forefront of technology development and strengthens our portfolio of genomics research," says Marc Lalande, director of UConn's Institute for Systems Genomics. "Also, thanks to the investments in genomics through the University's Academic Plan, Brent Graveley can leverage his expertise so that faculty and students across our campuses will successfully compete for grant dollars and launch bioscience ventures."
The researchers are planning to sequence every bit of RNA from beginning to end inside a single cell. This can't be done by traditional gene sequencers. This new technology is supposed to transform the way we study RNA biology and the type information.
Read more:http://www.cusabio.com/catalog-13-1.html

New report shows relationship between ecotourism and wildlife

More and more tourists are willing to vacation in far-flung places around the places where they can use their money to make a positive impact on local people and local wildlife. However, researchers published a report in Trends in Ecology & Evolution on October 9th showed that the interactions between wild animals and friendly ecotourists eager to snap their pictures may unintentionally put animals at greater risk of being eaten.
It is obvious that ecotourism business is booming these years. "Recent data showed that protected areas around the globe receive 8 billion visitors per year; that's like each human on Earth visited a protected area once a year, and then some!" said Daniel Blumstein of the University of California, Los Angeles. "This massive amount of nature-based and ecotourism can be added to the long list of drivers of human-induced rapid environmental change."
The report shows the viewpoint that when animals interact with humans in benign ways, they may lower their guard. As they get used to staying with humans in comfortable environment, they may become bolder in other situations. It is difficult for them to recognize real predators.
Ecotourism is actually similar to domestication or urbanization. In all three cases, regular interactions between people and animals may lead to habituation. This is another kind of taming. A process that results from evolutionary changes but also from regular interactions with humans happens: domesticated silver foxes become more docile and less fearful. Domesticated fish are less responsive to simulated predatory attacks. Fox squirrels and birds that live in urbanized areas are bolder. It takes more to make them flee.
Besides, the presence of humans can also scare off natural predators, which creates a relatively safe environment for the smaller animals which could have become bolder. When humans are around, for example, vervet monkeys have fewer run-ins with predatory leopards.
The researchers hope more research on the interactions of humans with wildlife can be stimulated by this research. It will help people understand how different species and species in different situations respond to human visitation and under what conditions human act may put these species in danger situation.
Read more:http://www.cusabio.com/catalog-9-1.html

2015年10月9日星期五

Scientists found new protein factors to control bacterial growth

It is well-known by those biochemists that crucial cell processes depend on a highly regulated cleanup system known as proteolysis, where specialized proteins called proteases degrade damaged or no-longer-needed proteins. These proteases must destroy their own targets but not damage other proteins. However, the process is still not very clear to the in many cases.
Recently, researchers in Peter Chien's group from the department of biochemistry and molecular biology at the University of Massachusetts Amherst report that they have found how an essential bacterial protease controls cell growth and division. You can read the details in the current issue of Cell.
The lead author of the report is Kamal Joshi, a doctoral candidate in the Chien lab. He conducted experiments in the model bacterium Caulobacter crescentus. In this species, the ability to grow and replicate DNA is regulated by ClpXP, a highly conserved protease that in many bacteria allows them to cope with stressful environments such as the human body. Understanding how ClpXP is controlled could open a path to antibiotics that inhibit harmful bacteria in new ways.
How proteolysis controls Caulobacter growth is still a secret in the field.
It is strange that ClpXP only destroys its target proteins at a specific time. They think there must be a factor they've ignored. There are some genetic evidence pointing to certain additional proteins, but no more details are discovered.
The lab purified all available proteins and designing experiments to query how they interacted and what functions were affected in their presence or absence. They found that the ClpXP protease could not by itself destroy the target proteins, and the additional regulatory proteins they had detected were controlling different parts of the process.
Later, they found these newly identified regulatory adaptors worked in a step-wise hierarchical way. The first adaptor was directly responsible for degrading a handful of proteins, but it could also recruit an additional adaptor that would deliver a different set of proteins and bind even more adaptors. Working with the Viollier lab from the University of Geneva, Switzerland, the researchers found scores of additional protease targets that were destroyed in this hierarchical way.
It is believed that this new fundamental knowledge may offer an entirely new target for developing new antibiotics with a high potential to avoid triggering drug resistance, because new compounds could be devised which would not simply target all bacterial growth, but only a specific pathway, such as virulence.
You don't force the benign bacteria to develop resistance in this approach because their growth isn't threatened. The hope is to target only those pathogenic organisms that are trying to overcome the stressful environment inside the human body.
Though the researchers haven't known if these adaptor factors are common among all bacteria, but they decide to figure out.
Read more:http://www.cusabio.com/catalog-13-1.html

Engineer stem cells to study leukemia better

In order to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, scientists engineered stem cells for leukemia. The study was led by Mount Sinai researchers and published in the journal Cell Reports online.
Before then, it had been established that inherited changes in the DNA code for the gene PTPN11 cause Noonan syndrome, a genetic disease that comes with a high risk for the blood cancer called juvenile myelomonocytic leukemia (JMML). Scientists still didn't know the mechanisms behind the disease and what influences its severity.
What's worse, currently the only treatment for JMML - a bone marrow transplant to replace the hematopoietic stem cells that become blood cells - is effective only in 50% of patients. This pushes scientists to step more toward designing better treatments.
"By studying an inherited human cancer syndrome, our study clarified early events in the development of one kind of leukemia," said corresponding study author Bruce D. Gelb, MD, Gogel Family Chair and Director of The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai. "More than just creating a model of a disease, we were able to prove that mechanisms seen in our model also happen in the bone marrow of people with this kind of leukemia. The work also provided new targets for the field to develop new drugs against in JMML."
In order to better understand diseases with a genetic component, scientists choose the approach of taking skin cells from patients with a disease and use enzymes to coax the cells back along the differentiation pathway to become induced pluripotent stem cells or iPSCs. Such cells can then be programmed to mature into cells including hematopoietic (blood) cells, which re-create a specific version of each person's genetic disease in a petri dish for study.
In the study, authors say that hematopoietic cells produced from induced stem cells with PTPN11 mutations known to cause JMML indeed act like cells seen in these patients. According to them, "gain of function" genetic changes that happen to increase this protein's expression were enough to cause leukemia-related changes in cells.
iPSCs used to model cancers are often created from cancer cells, a process with comes with a great many mutations (changes in the gene code) in genes that are part of the unstable, frequent cell division and multiplication seen in cancer. By starting with skin cells of JMML patients with inherited PTPN11 mutations, scientists could create JMML cells with only these mutations, screening out the "genetic noise" that can obscure disease mechanisms.
The results of the study show that the severity of this form of leukemia arises from the degree of changes in the gene PTPN11, altering the protein it codes for, SHP-2, and biologic pathways related to it. And these proteins promise to become a focus of future drug design efforts, According to Dr. Gelb.
Read more:http://www.cusabio.com/catalog-9-1.html

2015年10月8日星期四

Researchers develop a platform to recognize specific target antibodies

A new study may completely change the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV. An international research team have designed and synthetized a nanometer-scale DNA "machine" whose customized modifications enable it to recognize a specific target antibody. This new approach is said to support the development of rapid, low-cost antibody detection at the point-of-care, eliminating the treatment initiation delays and increasing healthcare costs associated with current techniques.
The binding of the antibody to the DNA machine causes a structural change which generates a light signal. The sensor does not need to be chemically activated and is rapid - in five minutes - enabling the targeted antibodies to be easily detected, even in complex clinical samples such as blood serum.
This DNA nanomachine is highly versatile that can be in fact custom-modified so that it can detect a huge range of antibodies, this makes our platform adaptable for many different diseases.
The modular platform provides significant advantages over existing methods for the detection of antibodies. It may prove to be useful in a range of different applications such as point-of-care diagnostics and bioimaging.
Besides, this platform has an advantage of low-cost. The materials needed for one assay cost about 15 cents, which makes the approach very competitive in comparison with other quantitative approaches.
These preliminary results make the researchers exciting. There are more to make this approach available to everyone.
Read more:http://www.cusabio.com/catalog-13-1.html

Observe living cells by use of a new DNA stain

Though bio-imaging is helpful to visualize the inner workings of a cell while it is still alive, the living cells put under the microscope risk being killed by the light and the fluorescent dyes used to highlight their structures. It is much like sunburnt - live cells are sensitive to intense light and the ultraviolet and blue lights used in live-cell imaging are the most dangerous. Now, EPFL scientists have developed a new DNA stain that can be used to safely image live mammalian cells for days even under demanding imaging conditions.
The work about this new DNA stain is published in Nature Communications.
Fluorescent stains that light up a cell's DNA allow people to track key biological processes such as cell division thus they are popular in live-cell imaging. But current DNA stains are themselves toxic or require types of light that can damage the cells. Ideally, a safe DNA fluorescent stain would be activated in the safer far-red spectrum of light.
What's more, a lot of DNA stains are not compatible with super-resolution microscopy, a modern imaging technique that can capture images of cells at higher resolution than that allowed by regular microscopes. So the bio-imaging community has been waiting for a DNA stain that shows low toxicity, works with far-red light and can be used in superresolution microscopy.
The lab of Kai Johnsson at EPFL has now developed a DNA stain that can satisfy all of the needs. The scientists combined two molecules together - One is a fluorescent molecule (silicon rhodamine or SiR) that works in the far-red spectrum and was previously developed in Johnsson's lab, and the other one is a well-known DNA stain Hoechst (the chemical name is bisbenzimide). Finally, the scientists named the DNA stain "SiR-Hoechst".
The new stain works by binding to a part of the DNA helix known as the "minor groove". Once bound, it turns on and emits a bright fluorescent red light. This is a tremendous advantage, as the stain produces very little noise - if it has not found its target, it stays "off". More importantly, SiR-Hoechst can bind to DNA without affecting its biological function in the cell. And because all cells possess DNA, the probe can be used across numerous species, types of cells, and tissues.
There is little risk of damage to cells because SiR-Hoechst works with far-red light. Besides, the light that it emits can be easily distinguished from any background fluorescence of living cells. These features give SiR-Hoechst a clear advantage over other DNA stains - it can safely maintain high-quality staining in live cells for over 24 hours, allowing biologists to identify individual cells in tissue or culture, or track delicate processes in real time.
This stain can be used in live-cell super-resolution imaging, helping to solve problems in DNA imaging in cells and biological tissues with exquisite resolution.
The SiR-Hoechst makes bioimaging safer. That is, it realizes the dream of observing details of nature without impacting them.
Read more:http://www.cusabio.com/catalog-9-1.html